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Essentials
• The Royal disease (RD) is a form of hemophilia B pre-
dicted to be caused by a splicing mutation.
• We generated an iPSC-based model of the disease
allowing mechanistic studies at the RNA level.
• F9 mRNA analysis in iPSC-derived hepatocyte-like cells
showed the predicted abnormal splicing.
• Mutated F9 mRNA level was very low but we also
found traces of wild type transcripts.
Summary. Background: The royal disease is a form of
hemophilia B (HB) that affected many descendants of
Queen Victoria in the 19th and 20th centuries. It was
found to be caused by the mutation F9 c.278-
3A>G. Objective: To generate a physiological cell model
of the disease and to study F9 expression at the RNA
level. Methods: Using fibroblasts from skin biopsies of a
previously identified hemophilic patient bearing the F9
c.278-3A>G mutation and his mother, we generated
induced pluripotent stem cells (iPSCs). Both the patient’s
and mother’s iPSCs were differentiated into hepatocyte-
like cells (HLCs) and their F9 mRNA was analyzed using
next-generation sequencing (NGS). Results and Conclu-
sion: We demonstrated the previously predicted aberrant
splicing of the F9 transcript as a result of an intronic
nucleotide substitution leading to a frameshift and the
generation of a premature termination codon (PTC). The
F9 mRNA level in the patient’s HLCs was significantly
reduced compared with that of his mother, suggesting
that mutated transcripts undergo nonsense-mediated
decay (NMD), a cellular mechanism that degrades PTC-
containing mRNAs. We also detected small proportions
of correctly spliced transcripts in the patient’s HLCs,
which, combined with genetic variability in splicing and
NMD machineries, could partially explain some clinical
variability among affected members of the European
royal families who had lifespans above the average. This
work allowed the demonstration of the pathologic conse-
quences of an intronic mutation in the F9 gene and repre-
sents the first bona fide cellular model of HB allowing the
study of rare mutations at the RNA level.
Keywords: factor IX; hemophilia B; high-throughput
nucleotide sequencing; induced pluripotent stem cells;
RNA splicing.
Introduction
The royal disease (RD) is a form of hemophilia B most
famously transmitted from Queen Victoria (1819–1901) to
the European royal families during the 19th and 20th cen-
turies. Because of its historical impact, it has attracted the
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attention of historians and biomedical researchers for dec-
ades. The mutation (F9 c.278-3A>G) was identified in
DNA from bone remains of members of the Russian royal
family. It was predicted to create an abnormal splicing site
two nucleotides ahead of the wild-type (wt) site in the F9
transcript, resulting in the inclusion of two additional
nucleotides at the exon 3/exon 4 boundary, a frameshift
and a premature termination codon (PTC) in the mature
mRNA [1]. This was functionally validated in a model
based on COS7 cells transfected with a minigene construct
(truncated intron 3 – exon 4 – truncated intron 4). How-
ever, this approach did not allow the capture of the com-
plexity of splicing of the full-length F9 transcript in
hepatocytes, thus limiting the impact of this study. Because
of the strict tissue specificity of the F9 promoter, a more
precise analysis of the molecular mechanism leading to the
bleeding phenotype would require studying F9 mRNA in
the hepatocytes of patients carrying this mutation.
We previously identified an 18-year-old Spanish
patient with severe hemophilia B (HB), unrelated to the
royal family, carrying this mutation [2]. The basal levels
of coagulant factor (F) IX were < 1% in the patient
and in the range of 30–40% in the carrier mother. A
detailed description of the clinical history of this patient
was previously reported [2]. The carrier has a history of
hematomas, menorrhagia and bleeding episodes after
minor surgeries, for which she has received replacement
therapy with recombinant FIX. In the patient, a more
sensitive quantification of his endogenous FIX plasma
levels was not possible because he has been on prophy-
lactic treatment since the age of 3 years and a liver
biopsy to study F9 mRNA was precluded for ethical
reasons. To circumvent these limitations, we took
advantage of the induced pluripotent stem cell (iPSC)
technology to create a cellular model that captured the
patient’s genomic complexity and to study a more phys-
iological F9 expression upon in vitro differentiation into
hepatocyte-like cells (HLCs).
Materials and methods
Human subjects
Diagnosis of the patient’s HB and of the mother’s carrier
status was clinically and genetically confirmed at the
Hemophilia Unit of Vall d’Hebron University Hospital
[2]. Both mother and son agreed to undergo a skin biopsy
for this study and signed a written informed consent pre-
viously approved by our institutional Ethics Committee
and Review Board, which also approved the study.
Generation and maintenance of HB-patient-specific iPSCs
(HB-iPSCs)
A 3-mm full-thickness skin punch biopsy was obtained
from the volar surface of the forearm. The biopsy
specimen was cut into 30–40 ~0.5-mm pieces and plated
in HDF medium (DMEM containing 10% fetal bovine
serum [FBS], 2 mM GlutaMAX, 50 U mL1 penicillin
and 50 mg mL1 streptomycin [all from Gibco/Thermo
Fisher Scientific, Waltham, MA, USA]). Primary cultures
of fibroblasts were reprogrammed to pluripotency by
retroviral transduction with a 1 : 1 : 1 : 1 mixture of
retroviruses encoding FLAG-tagged Oct4, Sox2, Klf4 and
c-Myc, as previously described [3]. Transduced cells were
trypsinized and seeded onto irradiated CCD1112Sk
(ATCC CRL2429) human foreskin fibroblasts (irrHFF)
2–3 days after infection. One day later, the medium was
replaced with hESC medium (KO-DMEM supplemented
with 20% KO-serum replacement, 2 mM Glutamax,
50 mM 2-mercaptoethanol, non-essential amino acids [all
from Gibco/Thermo Fisher Scientific] and 10 ng mL1 of
human FGF-basic [Peprotech, Rocky Hill, NJ, USA]).
Cells were maintained at 37 °C in 5% CO2 and the med-
ium was changed daily until iPSC colonies appeared.
These patient-specific iPSC lines were maintained and
passed by mechanical dissociation of the colonies, at a
1 : 3 ratio, and cultured on a feeder layer of irrHFF with
hESC medium. Alternatively, the colonies were subjected
to limited trypsin digestion and passaging onto Matrigel-
coated plates with hESC medium pre-conditioned by irra-
diated mouse embryonic fibroblasts (MEFs).
Characterization of HB-iPSC lines
The patient-specific iPSC lines were characterized as pre-
viously described [3]. Briefly, the iPSC lines were selected
based on colony morphology, growth characteristics, and
the capacity to sustain long-term passaging (> 20 pas-
sages) while maintaining a normal karyotype. Alkaline
phosphatase (AP) activity was measured using an AP
blue/red membrane substrate solution kit (Sigma, St
Louis, MO, USA) according to the manufacturer’s guide-
lines. The expression of pluripotency-associated nuclear
factors (OCT4, SOX2 and NANOG) and surface markers
(SSEA3, SSEA4, TRA1-60 and TRA1-81), and the
in vitro pluripotent differentiation ability of the cells to
endoderm, mesoderm and neuroectoderm were analyzed
by immunofluorescence as previously described [4]
(Fig. 1). Briefly, the cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) at
room temperature (RT) for 10 min, permeabilized for
15 min in 0.5% Triton in PBS, and then blocked for 2 h
in Triton-X100 with 3% donkey serum (Millipore, Darm-
stadt, Germany). The primary antibodies used in all
immunophenotypic studies are listed in Table S1. Second-
ary antibodies were of the Alexa Fluor series from Jack-
son ImmunoResearch (West Grove, PA, USA), and used
at a 1 : 250–1 : 500 dilution. Images were taken using a
Leica SP5 confocal microscope. Cell nuclei were counter-
stained with 0.5 lg mL1 DAPI (40,6-diamidino-2-pheny-
lindole).
© 2017 International Society on Thrombosis and Haemostasis
A cellular model of the royal disease 2189
H
B-
28
H
B-
16
100 um
100 um 100 um 100 um 100 um
100 um 100 um 50 um
OCT-4/SSEA3/DAPI SOX-2/SSEA4/DAPI NANOG/TRA-1-81/DAPI
TU
J1
/G
FA
P
AF
P/
FO
XA
2
G
AT
A4
/α
-
AC
TI
N
HB-16
HB-28
Clone 1
Clone 2
Clone 3
Clone 4
Clone 5
Clone 1
Clone 2
Clone 3
Clone 4
Ec
to
de
rm
En
do
de
rm
M
es
od
er
m
40
35
30
25
20
15
10
5
0
80
70
60
50
40
30
20
10
0
En
do
KL
F4
En
do
cM
YC
En
do
OC
T4
En
do
SO
X2
Tra
ns
KL
F4
Tra
ns
cM
YC
Tra
ns
OC
T4
Tra
ns
SO
X2
CR
IPT
O
NA
NO
G
RE
X
HB-28HB-16
1 2 3 4 5 1 2 3 4 5
6 7 8 9 10 11 12 6 7 8 9 10 11 12
13
19 20 21 22 X Y 19 20 21 22 X Y
14 15 16 17 18 13 14 15 16 17 18
G
en
e 
ex
pr
es
sio
n 
re
la
tiv
e
 to
 G
AP
DH
 (%
)
100 um 100 um
100 um
100 um 100 um
100 um
A
B
D
C
© 2017 International Society on Thrombosis and Haemostasis
2190 L. Martorell et al
Silencing of the reprogramming transgenes (Oct4, Sox2,
Klf4 and c-Myc) and activation of the endogenous
pluripotency-associated genes (OCT4, NANOG, CRIPTO
and REX1) in HB-iPSCs were confirmed as follows. Tri-
zol-extracted total RNA and the SuperScript III Reverse
Transcriptase kit (Life Technologies/Thermo Fisher Scien-
tific, Carlsbad, CA, USA) were used for first-strand
cDNA synthesis. A qPCR was then performed using
SYBR Green PCR Mastermix (Life Technologies/Thermo
Fisher Scientific) and the following thermocycling param-
eters: initial denaturation for 10 min at 95 °C and then
40 cycles of 95 °C for 15 s and 60 °C for 1 min, ending
with a dissociation curve stage. Non-transduced primary
cells served as the negative control, and GAPDH as the
endogenous control. The regulatory sequences of interest
were amplified by two subsequent PCRs using the primer
pairs indicated in Table S2. The resulting amplified prod-
ucts were cloned using the Dual Promoter TA Cloning
kit (Life Technologies/Thermo Fisher Scientific), ampli-
fied in DH5a cells, purified and sequenced. A minimum
of two iPSC clones from each of the patient and his
mother were selected that fulfilled all these criteria. Fro-
zen stocks of early (< 10) and late (> 20) passage cells
were stored in liquid N2.
Short tandem repeat (STR) analysis
To confirm that the iPSCs originated from the patient
and his mother, DNA from PBMCs, fibroblasts and iPSC
samples was subjected to STR analysis using the
AmpFLSTR Identifiler PCR amplification kit (Applied
Biosystems, Foster, CA, USA) as previously described [2].
Hepatic differentiation of HB-iPSCs
Hepatic differentiation was induced using a protocol that
mimics liver development in vivo [5], with a few modifica-
tions (Fig. 2A). Briefly, iPSC clones were cultured for 2
days in chemically defined medium supplemented with
polyvinyl alcohol (CDM-PVA) (50% F12 GlutaMAX
[Gibco] + 50% IMDM [Gibco] supplemented with 1%
concentrated lipid + 450 lM thioglycerol + 7 lg mL1
insulin + 15 lg mL1 transferrin [Roche, Basel, Switzer-
land] + 1% Pen/Strep + polyvinyl alcohol [Sigma, Saint
Louis, MO, USA] + 100 ng mL1 Activin A [Pepro-
tech] + 80 ng mL1 fibroblast growth factor [FGF] 2
[R&D Systems, Minneapolis, MN, USA]), 2 days in
CDM-PVA medium + 100 ng mL1 Activin A +
80 ng mL1 FGF2 + 10 ng mL1 bone morphogenetic
protein (BMP) 4 (R&D Systems) + 10 lM Ly294002 (Cal-
biochem, Merck Millipore, Billerica, MA, USA) + 3 lM
Chir99021 (Stemgent, Miltenyi Biotec, Bergisch Glad-
bach, Germany) and 1 day without Chir99021. Definitive
endoderm differentiation was then specified by incubation
with RPMI1640/B27 (Life Technologies) + 100 ng mL1
Activin A + 80 ng mL1 FGF2 for 1 day and RPMI/
B27 + 50 ng mL1 Activin A for 2 additional days.
Finally, the differentiation of hepatoblasts was driven by
incubation in RPMI1640/B27 + 20 ng mL1 BMP4 +
10 ng mL1 FGF10. Cells were passaged on collagen I-
coated plates on day 11 and cultured in a hepatocyte cul-
ture medium (Lonza, Levallois, France) + 20 ng mL1
hepatocyte growth factor (HGF) (Peprotech) + 20 ng
mL1 Oncostatin M (Peprotech) + 0.1 mM dexametha-
sone (Sigma) until day 27.
Immunofluorescence of iPSC-derived HLCs
iPSC-derived cells were washed twice with PBS and fixed
with 4% paraformaldehyde (Euromedex, Souffelweyer-
sheim, France) for 15 min at room temperature (RT) fol-
lowed by three washes with PBS. The fixed cells were
permeabilized with 0.1% Triton X-100 for 15 min and
blocked for 1 h with 3% bovine serum albumin (BSA)
(Sigma) in PBS. The cells were then incubated with the
primary antibodies (Table S1) overnight at 4 °C in the
presence of 1% BSA in PBS. After three washes with
PBS, they were incubated with the secondary antibodies
(1 : 1000) in the dark with agitation for 1 h at RT. Cell
nuclei were visualized by DAPI staining (0.5 lg mL1)
(Sigma), mounting the cells on glass slides with Fara-
mount Aqueous mounting medium (Dako/Agilent Tech-
nologies, Santa Clara, CA, USA). Images were obtained
using the EVOS FL Auto microscope and its software
(Thermo Fisher Scientific).
RNA isolation, RT-PCR and qPCR
Total RNA was isolated using the RNeasy Mini kit (Qia-
gen, Hilden, Germany) or Trizol (Invitrogen, Rockville,
MD, USA) according to the manufacturers’ recommenda-
tions. HB-iPSCs and iPSC-derived HLCs were also tested
by RT-PCR to analyze the expression of specific markers
during hepatic differentiation (days 0, 5, 11 and 21,
Fig. 1. Characterization of royal disease (RD) patient’s and mother’s induced pluripotent stem cells (iPSCs). (A) Alkaline phosphatase (AP)
staining of representative iPSC colonies hemophilia B (HB)-28 (mother) and HB-16 (patient) (left), and immunofluorescence images showing
expression of the pluripotency markers OCT4, SOX2, SSEA3 and 4, NANOG and TRA-1-81. (B) Relative expression of endogenous and
exogenous pluripotency genes detected by RT-qPCR using specific primers (Table S3). iPSC clones were selected based on the activation of
endogenous (endo) genes associated with pluripotency and the silencing of (exogenous) transgenes. (C) iPSCs could be differentiated into the
three germ layers, as confirmed by the expression of specific markers detected using immunofluorescence (endoderm, AFP and FOXA2; meso-
derm, smooth muscle a-actin (SMA) and GATA4; ectoderm, TUJ1 and GFAP) (see Table S1 for the antibodies used). (D) Normal karyotype
of HB-16 (46XY, left) and HB-28 iPSCs (46XX, right), analyzed at passages 15 and 7, respectively. [Color figure can be viewed at wileyonlineli-
brary.com]
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corresponding to the pluripotent state, endoderm, hepatic
progenitors and mature hepatocytes, respectively). A total
of 500 ng of total RNA extracted with the RNeasy Mini
Kit (Qiagen) in a final volume of 25 lL were retrotran-
scribed using the High-Capacity cDNA reverse transcrip-
tion kit (Thermo Fisher Scientific), according to the
manufacturer’s recommendations. An equal amount of
cDNA was used to establish the expression of OCT4,
NANOG, GATA4, SOX17, FOXA2, AFP, HNF4, ALB,
CK18, CK19, CYP34A and F9 (primers listed in
Table S2).
For quantitative analyses of factor F9 mRNA in
HLCs, RT-qPCR was performed using TaqMan Univer-
sal Master Mix II, with uracil n-glycosylase (Thermo
Fisher Scientific) according to the manufacturer’s instruc-
tions. GAPDH (4333764F) served as the endogenous con-
trol and F9 mRNA was detected in a Taqman assay
(Hs_01592597_m1).
F9 mRNA sequencing
Total RNA was retrotranscribed using the High Capacity
cDNA reverse transcription kit (Thermo Fisher Scientific)
as described above. The primers for massive sequencing
were designed using the F9 cDNA (GenBank no.
NM_000133.3) to amplify the affected region of F9
mRNA, resulting in a 340-bp amplicon (A region)
(Fig. 3A and Table S2). Cells from the human hepatocel-
lular carcinoma cell line Huh-7 or adult primary hepato-
cytes (obtained from liver biopsies) served as positive
controls. After cDNA synthesis, the three amplicons
described in Fig. 3A were amplified using the FastStart
High Fidelity PCR system (Roche Diagnostics, Basel,
Switzerland) with an initial denaturation at 94 °C for
3 min, 30 cycles at 94 °C for 30 s, 65 °C for 30 s, and
72 °C for 1 min, followed by a final extension at 72 °C
for 3 min. The PCR products were specifically indexed,
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Fig. 2. Characterization of hepatocyte-like cells (HLCs) derived from hemophilia B (HB)-16 and HB-28 induced pluripotent stem cell (iPSC)
clones. (A) Protocol used for iPSC differentiation into HLCs. Phase-contrast microscopy shows the morphology of the cells at days 0 (left) and
27 (right) of differentiation. (B) RT-PCR analyses showing the expression pattern during hepatic differentiation of both HB-16 and HB-28
iPSC clones. (C) Expression of hepatocyte markers analyzed by immunofluorescence in patient’s (HB-16-derived) HLCs. The same hepatocyte
markers were observed with HB-28 HLCs (data not shown). AFP, a-fetoprotein; APOA2, apolipoprotein A2; ASGR, asialoglycoprotein recep-
tor; A1AT, a1-anti-trypsin; CK19, cytokeratin 19; CYP3A4, cytochrome P450 3A4; FOXA2 and HNF4a, hepatocyte transcription factors.
[Color figure can be viewed at wileyonlinelibrary.com]
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separated on a 1% agarose gel, and visualized by Syber
Safe staining (Thermo Fisher Scientific). They were then
quantified with the Qubit dsDNA BR assay kit in a
Qubit fluorometer, normalizing the amounts using the
SequalPrepTM normalization plate kit (Thermo Fisher Sci-
entific). The normalized products were sequenced in a
Miseq sequencer using a Miseq reagent Nano kit v2 (Illu-
mina, San Diego, CA, USA). The obtained sequences
were assembled and aligned with the consensus wt F9
cDNA sequence using the software CLC Genomics
Workbench (Qiagen).
X chromosome inactivation analysis
The pattern of X inactivation was determined using the
HUMARA assay with some modifications [6]. Briefly,
genomic DNA was digested overnight with the methyla-
tion-sensitive Hpa II endonuclease, coupled with PCR
analysis using FAM-fluorescently labeled primers. The
amplified products were separated using an ABI 3130
genetic analyzer (Applied Biosystems) as previously
described [7]. The fragment size was estimated by com-
parison with the internal size standard Gene Scan ROX
(Applied Biosystems).
Results
Patients, iPSC generation and characterization
Skin biopsies were taken from the patient and his mother
and the subsequently isolated fibroblasts were repro-
grammed using c-retroviral vectors encoding the four
Yamanaka factors. Among all the colonies that were gen-
erated and isolated, representative colonies from the
patient and the mother were selected, amplified and fully
characterized as iPSC clones [3,4].
The stemness of the iPSCs was confirmed by (i) positive
staining for AP (Fig. 1A); (ii) immunofluorescence-based
detection of the expression of stem cell markers (Fig. 1A,
Table S1); (iii) silencing of the transduced genes and
induction of endogenous pluripotency genes (Fig. 1B);
and (iv) the presence of early derivatives of the three
germ layers after spontaneous differentiation in vitro
(Fig. 1C). HB-iPSCs maintained a normal karyotype
(Fig. 1D) and short tandem repeat (STR) analysis con-
firmed the origin of the iPSC clones (Table S3). One iPSC
clone for the patient and one for the mother, named HB-
16 and HB-28, respectively, were selected for further
studies.
iPSC differentiation into HLCs
Hepatocytes are the only cells of the body that express
full-length F9 mRNA and produce functional FIX. HB-
16 and HB-28 iPSCs were thus differentiated into HLCs
by adapting a protocol mimicking normal liver
development, as previously described [5], (Fig. 2A). Dur-
ing this process, cells were first differentiated into defini-
tive endoderm cells expressing FOXA2 at day 5 (Fig. 2B);
then they were committed into bipotent hepatic progeni-
tors co-expressing hepatocytic and biliary markers
(HNF4a, AFP, APOA2 and CK19) at day 10 (Fig 2B, C,
left panels). Finally, at day 27, cell morphology closely
resembled that of hepatocytes (Fig. 2A, right picture) and
HLCs expressed mature hepatocyte markers such as
CYP3A4, ASGR, albumin and A1AT (Fig 2B, C, right
panels). We thus amplified exons 2–8 of F9 RNA, a
region that can only be amplified using hepatocyte- or
HLC-derived RNA that covers the patient’s mutation,
from both HB-16 and HB-28-HLC RNA.
Molecular analyses of F9 mRNA
RT-qPCR of F9 mRNA from HLCs and comparisons
with primary hepatocyte F9 mRNA levels showed a rela-
tive expression level of 36.9%  2.7 in the mother’s and
2.1%  0.7 in the patient’s HLCs (Fig. 3B). The incom-
plete differentiation/maturation into hepatocytes may
account for the low level of F9 mRNA expression in the
HB-28 HLCs compared with primary hepatocytes, but it
does not explain its much lower expression in the HB-16
HLCs. Indeed, HLCs from both the patient and the
mother exhibited the same pattern of differentiation
markers with no striking differences between them. How-
ever, nonsense-mediated decay (NMD), a cellular mecha-
nism that degrades PTC-containing mRNAs, could
explain the very low level of F9 mRNA observed in the
HB-16 HLCs that express only the mutated transcript.
Nevertheless, the interpretation of the level of F9 mRNA
expression in HB-28 HLCs must take into account from
which X chromosome the F9 transcripts are issued.
Indeed, the X-chromosome inactivation pattern (XCIP)
could have been modified during reprogramming of the
mother’s skin fibroblasts into HB-28 iPSCs [8]. Thus,
depending on the actual XCIP pattern, either or both of
the normal and mutated F9 transcripts could be expressed
in the HB-28 HLCs. To elucidate this point and to deeply
analyze the sequence of the mutated transcript, we per-
formed NGS analysis. We used three different sets of pri-
mers to amplify F9 mRNA by RT-PCR in the HLCs
(Fig. 3A, C).
Amplicon sequencing showed the creation of an abnor-
mal splicing site in the vast majority of the transcripts
from HB-16 HLCs that resulted in the inclusion of two
additional nucleotides to F9 mRNA in the exon 3/exon 4
boundary, leading to a frameshift and the generation of a
PTC (Fig. 3A), as previously predicted [1]. However, the
remaining 2.9% of the reads displayed the wt sequence
(Table 1, Fig. 3D), suggesting some normal splicing of
the mutated transcript and the existence of a residual
FIX expression, although very limited if we take into
account that the F9 mRNA expression was very low in
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HB-16 HLCs. F9 mRNA analysis of HB-28 HLCs indi-
cated an extremely low percentage (0.1%) of mutated
transcripts (Table 1), which led us to investigate the
XCIP in the HB-28 iPSCs and the derived HLCs. Analy-
ses using the HUMARA assay showed that the X-chro-
mosome carrying the mutation was inactivated in the
HB-28-iPSC clone and in all derived HLCs (Figure S1).
This result explains the nearly exclusive presence of wt F9
mRNA in HB-28 HLCs. Moreover, this result supports
the hypothesis of the degradation of the mutated tran-
script by NMD in the HB-16 HLCs to explain the
reduced level of F9 mRNA in those cells compared with
HB-28 HLCs. Finally, by combining the proportion of F9
mRNA detected in HB-16 HLCs with respect to the levels
observed in primary hepatocytes (about 2%) and the per-
centage of this mRNA that we found correctly spliced
(about 3%), despite the limitations of this cellular model
in mimicking the RD, we can roughly estimate that the
total wt F9 mRNA level in these RD HLCs is around
0.06% (3% of correctly spliced mRNA out of the 2% of
the total F9 mRNA level with respect to that of normal
hepatocytes; see Table 1), which is consistent with the
patient’s severe phenotype.
Discussion
The present work describes the creation of a cellular
model of HB, based on the iPSC paradigm. In this case,
it allowed us to generate patient-specific HLCs carrying
the RD mutation, to isolate hepatocyte-specific F9
mRNA and to fully characterize the splicing mutation by
NGS in a more physiological context. It also represents
the first definitive demonstration, in the absence of
currently living descendants, that the F9 c.278-3A>G
mutation is truly responsible for the hemophilic syndrome
in the affected members of the European royal families.
In addition, these results represent advances in two fields:
first, it is the first time that HB has been modeled using
patient-specific iPSCs, and second, it allows a more physi-
ological (and thus more relevant) characterization of this
mutation in comparison with that of a previous report
that could only predict some of the consequences of this
splicing mutation at the RNA level, as it was based on an
artificial minigene-based system. The present work, which
relies on the use of HLCs expressing F9 mRNA, confirms
the previously predicted consequences of the mutation at
the RNA level, and provides novel information that could
not be anticipated with the previously used approach.
Indeed, in the case of intronic splicing mutations such as
this one, F9 transcripts must be analyzed, and this
requires either primary cells of the relevant tissue (e.g.
hepatocytes) or HLCs generated from the patient’s iPSCs.
However, in our case, because primary hepatocytes could
not be obtained, the only way to get a real and meaning-
ful picture of what occurs in the patient’s hepatocytes
was to differentiate the patient’s iPSCs into HLCs. It is
not possible to draw definitive conclusions on the reality
of the abnormal splicing unless the entire mutated F9
gene is expressed in hepatocytes or HLCs.
These results also provide new knowledge that may
help in understanding the long-discussed issue of the
unexpectedly high longevity (given the severity of the RD
and the absence of existing replacement therapies at that
time) of certain affected members of the European royal
families. Indeed, one of the most intriguing aspects of the
disease is that the average life expectancy of some
Table 1 NGS analysis of F9 mRNA amplicons
% of F9 mRNA
(with respect
to HPHs)
Total #
of reads
# of
mutated
reads
% of mutated
reads
# of wild-type
reads
% of wild-type
reads
% of wild-type
F9 mRNA/HPHs
(column 2 9 column 7)
HB-16 (patient) 2.1  0.7 434225 421546 97.1 12679 2.9 0.06
HB-28 (mother) 36.9  2.7 1049194 1049 0.1 1038702 99.9 36.86
HPHs, human primary hepatocytes.
Fig. 3. F9 mRNA expression in induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (HLCs). (A) Location of the mutation (F9
c278-3A>G) and the regions amplified by RT-PCR (region A, from exons 2–5: 340 bp; region B, from exons 5–8: 478 bp; region C, exons 2–8:
797 bp), and Sanger sequencing showing inclusion of the AG dinucleotide (red box) at the exon 3/exon 4 boundary, as a result of an abnormal
splicing. (B) Relative F9 mRNA levels were measured by RT-qPCR during cell differentiation using the Taqman assay (Hs_01592597_m1) and
GAPDH (4333764F) as the endogenous control. The results are expressed as the mean percentages of the control levels, measured in primary
human hepatocytes (n = 3). F9 mRNA expression level in hemophilia B (HB)-16 HLCs was 2.05%  0.65 (n = 5) on day 27 of differentiation,
whereas in HB-28 HLCs expression was first detectable on day 10 and reached 36.9%  2.71 (n = 5) on day 27. Error bars represent standard
deviations. (C) Representative F9 mRNA amplification in HB-16 HLCs on day 27. (D) F9 mRNA massive sequencing. Illumina GA analysis
of sequences spanning the affected exons of the F9 mRNA provided relatively uniform sequence coverage, with a sequencing depth for each
nucleotide position in the range of ~6000 to 30000 reads. The abnormal dinucleotide inclusion in the F9 mRNA resulting from the F9 c.278-
3A>G mutation was the only unambiguous genetic variant identified in the analysis. The reads containing the exon 3 and 4 joining were
extracted and aligned with the F9 reference sequence. Pie charts show the percentages of mutated (red) and wt (green) amplicons from F9
mRNA transcripts in HB-16 and HB-28 HLCs. Hep, primary human hepatocytes; MW, molecular weight, 100 bp ladder; CT-, negative
control. [Color figure can be viewed at wileyonlinelibrary.com]
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affected European royalty members was clearly longer
than that of contemporary or even more recently docu-
mented untreated patients with severe HB, estimated to
be 11-25 years [9,10]. Indeed, although some affected
members died at a very early age, others lived for several
decades, such as Prince Leopold (1853–1884), Prince
Waldemar of Prussia (1889–1945) or Alfonso and Gon-
zalo de Borbon (1907–1933 and 1914–1934, respectively,
who were killed in car accidents).
These observations of historical records, along with
previous reports showing a correlation between residual
expression of F8 mRNA and hemophilia A (HA) severity
[11], suggest the possibility that some affected individuals
might have suffered a less severe form of the disease.
However, considering (i) the FIX activity (< 1%) at the
time of diagnosis in the HB-16 patient and (ii) the fact
that the F9 c.278-3A>G mutation was also reported by
others as severe [12–14], it seems unlikely that the very
low residual level of wt F9 mRNA that we detect could
have resulted in a moderate phenotype in the affected
members of the royal families, unless there are other
sources of variability. The confirmation of the predicted
splicing mutation and the finding that mutated F9 mRNA
could be targeted by NMD, represent novel variables sup-
porting this notion, as it has been shown that variability
in the efficiencies of splicing [15,16] and NMD [17]
machineries (e.g. in the expression levels or the existence
of more or less active variants of the involved proteins)
can result in huge inter-individual phenotypic differences.
Indeed, a study carried out on 10 patients with cystic
fibrosis and the 3849 + 10 kb C>T mutation showed a
high percentage of variability (0–28%) in the levels of
aberrantly spliced RNA transcribed in their nasal epithe-
lia [15]. Thus, it is tempting to speculate, although this is
merely theoretical, that these and/or other additional
genetic traits might have attenuated the bleeding pheno-
type in some affected individuals of the royal families,
although other socio-economic considerations, including
special care received by these privileged individuals, may
also have played an important role.
In summary, we report the first iPSC-based cellular
model of HB. This technology allowed us to establish a
bona fide HB model to characterize rare mutations, such
as the one causing the RD, and we propose its use as a
powerful tool to elucidate mutational mechanisms at the
RNA level and to investigate correction strategies by gene
therapy, genome editing and/or drugs targeting specific
mutations.
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